Sofinnova Partners

SafeHeal is a medical device company specializing in digestive surgery. It develops and manufactures a vacuum-based, flexible bypass sheath designed to protect a gastrointestinal anastomosis after colorectal cancer surgery, remaining in place during healing to reduce ostomy needs and support postoperative recovery. The company originated as the first venture created and incubated by MD Start, a medtech accelerator, with backing from MD Start and Sofinnova Partners.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Berry Street specializes in online telehealth services for nutrition therapy. It connects patients with board-certified dietitians via video and chat platforms, covering areas such as disordered eating, heart health, PCOD, liver disease, women's health, sports nutrition, and diabetes. Berry Street is accepted by many insurance plans, making its services accessible to a wide range of individuals seeking to improve their health and quality of life.

Bioptimus develops a universal AI foundation model that connects biological data across different scales, from molecules to entire organisms. This enables clients to derive actionable insights and accelerate biomedical innovation.

nChroma Bio is a biotechnology company specializing in targeted genetic medicine. It operates an integrated product engine for safe, accurate, and targeted in vivo administration, aiming to overcome limitations of current genetic medicine techniques. The company focuses on liver-targeted therapies, initially for chronic hepatitis B and D, leveraging epigenetics to enable precise and specific gene regulation. This approach allows for therapies with programmable tissue specificity, potentially offering durable and targeted cures for the liver and other organs.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Purespring Therapeutics specializes in developing gene therapies targeting kidney diseases, focusing on podocytes, specialized kidney cells. It is one of the first globally to use AAV gene therapy specifically for kidney conditions.

Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.

deepc GmbH, based in Munich, Germany, specializes in artificial intelligence software for medical imaging, particularly in the field of radiology. The company has developed a disease-agnostic AI solution that screens medical imaging data in real-time, identifying healthy and non-healthy cases to prevent diagnostic errors. Its innovative web-based platform serves as a comprehensive operating system for diagnostics, allowing medical professionals and AI developers to seamlessly integrate diagnostic AI and other digital tools into clinical workflows. By enhancing the quality of diagnoses and improving cost-efficiency, deepc aims to facilitate immediate access to accurate diagnostics for individuals worldwide. The company has received recognition for its contributions to healthcare, including awards from the Federal Ministry for Economic Affairs and Energy.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

Endoron Medical develops a catheter-based device to secure endografts during endovascular aneurysm repair. The treatment uses a stapling mechanism that mimics hand-sewn suturing by deploying multiple staples around the aortic circumference to achieve transmural attachment of the stent graft to the aortic wall. The device aims to reduce endoleaks and graft migration and to enable treatment of complex abdominal aortic aneurysm anatomies by improving fixation and sealing of the endograft.

Cure51 is a company focused on advancing cancer treatment through the development of a clinical and molecular database. Its primary mission is to create a comprehensive database of cancer survivors, utilizing their unique biological characteristics to identify potential drug targets. By analyzing the biology of long-term cancer survivors, Cure51 aims to aid healthcare researchers in decoding genetic information derived from biopsies, blood tests, imaging, and other samples. This innovative approach seeks to accelerate drug discovery, ultimately contributing to the formulation of new and effective cancer therapies.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Bioptimus develops a universal AI foundation model that connects biological data across different scales, from molecules to entire organisms. This enables clients to derive actionable insights and accelerate biomedical innovation.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

Freya Biosciences is a clinical-stage company specializing in women's health. It develops microbial immunotherapies, focusing on unmet needs across various indications.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Gradient Denervation Technologies develops an endovascular catheter-based medical device designed to treat pulmonary hypertension by reducing pulmonary vascular resistance and improving cardiovascular hemodynamics. Founded in 2019, the company is headquartered in Paris, France.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies for inherited retinal disorders. It builds on proprietary Adeno-Associated Virus vector platforms designed to overcome cargo capacity limits of standard AAV vectors, enabling delivery of large genes to ocular tissues and other tissues in vivo, with the aim of treating genetic eye diseases and related conditions.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

Moon Surgical is a medical device company focused on enhancing minimally invasive surgical procedures through advanced robotics. The company is developing the Maestro System, a surgical robot designed to assist in laparoscopy by improving access to these techniques and optimizing the use of resources in the operating room. This technology provides surgeons with enhanced control and adaptability to various surgical conditions, thereby increasing efficiency and improving patient care. Moon Surgical's devices facilitate the stabilization and automatic positioning of endoscopes, as well as organ retraction, while maintaining the traditional surgical workflow. Through its innovative approach, Moon Surgical aims to transform surgical practices and enhance the overall surgical experience for both surgeons and patients.

Kiro develops an AI-powered digital health platform that enhances the relevance of lab test results for healthcare professionals and patients. Its tool provides personalized, understandable interpretations of medical biology reports using artificial intelligence to aid clinical decision-making, engage patients, and improve healthcare outcomes.

deepc GmbH, based in Munich, Germany, specializes in artificial intelligence software for medical imaging, particularly in the field of radiology. The company has developed a disease-agnostic AI solution that screens medical imaging data in real-time, identifying healthy and non-healthy cases to prevent diagnostic errors. Its innovative web-based platform serves as a comprehensive operating system for diagnostics, allowing medical professionals and AI developers to seamlessly integrate diagnostic AI and other digital tools into clinical workflows. By enhancing the quality of diagnoses and improving cost-efficiency, deepc aims to facilitate immediate access to accurate diagnostics for individuals worldwide. The company has received recognition for its contributions to healthcare, including awards from the Federal Ministry for Economic Affairs and Energy.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Mablink Bioscience is a biotechnology company focused on developing a new class of cancer therapies known as Antibody Drug Conjugates (ADCs). The company specializes in designing homogeneous, plasma-stable ADCs that maintain their original pharmacological properties while achieving a high drug-to-antibody ratio (DAR). This innovative approach aims to provide healthcare professionals with enhanced treatment options for cancer patients, ultimately improving therapeutic outcomes.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Moon Surgical is a medical device company focused on enhancing minimally invasive surgical procedures through advanced robotics. The company is developing the Maestro System, a surgical robot designed to assist in laparoscopy by improving access to these techniques and optimizing the use of resources in the operating room. This technology provides surgeons with enhanced control and adaptability to various surgical conditions, thereby increasing efficiency and improving patient care. Moon Surgical's devices facilitate the stabilization and automatic positioning of endoscopes, as well as organ retraction, while maintaining the traditional surgical workflow. Through its innovative approach, Moon Surgical aims to transform surgical practices and enhance the overall surgical experience for both surgeons and patients.

SafeHeal is a medical device company specializing in digestive surgery. It develops and manufactures a vacuum-based, flexible bypass sheath designed to protect a gastrointestinal anastomosis after colorectal cancer surgery, remaining in place during healing to reduce ostomy needs and support postoperative recovery. The company originated as the first venture created and incubated by MD Start, a medtech accelerator, with backing from MD Start and Sofinnova Partners.

Endoron Medical develops a catheter-based device to secure endografts during endovascular aneurysm repair. The treatment uses a stapling mechanism that mimics hand-sewn suturing by deploying multiple staples around the aortic circumference to achieve transmural attachment of the stent graft to the aortic wall. The device aims to reduce endoleaks and graft migration and to enable treatment of complex abdominal aortic aneurysm anatomies by improving fixation and sealing of the endograft.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Leucid Bio is a biotechnology company focused on developing cell therapies for refractory solid tumors. It translates over two decades of King's College London research in CAR-T therapies, led by an experienced management team with scientific and commercial expertise.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating first-in-class cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. Utilizing a proprietary siRNA-based screening technology, iOmx systematically analyzes human tumor cells to identify innovative therapeutic targets and understand their mechanisms of action. The company's approach is rooted in the principles of cancer immune-checkpoint therapy, which aims to overcome tumors' inherent resistance to immune attacks. This resistance is often mediated by cell surface molecules that inhibit T cell activation. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies for inherited retinal disorders. It builds on proprietary Adeno-Associated Virus vector platforms designed to overcome cargo capacity limits of standard AAV vectors, enabling delivery of large genes to ocular tissues and other tissues in vivo, with the aim of treating genetic eye diseases and related conditions.

Mnemo Therapeutics is a biotechnology company developing immune-based therapies, including cell therapies. Its EnfiniT platform uses epigenetic variation and CAR-T precision genetic engineering technology to target tumorous epitopes across various cancers.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Enthera is an Italian biotechnology startup established in October 2016 by BiovelocITA, Professor Paolo Fiorina, and Dr. Francesca D'Addio. The company specializes in developing biotherapeutics aimed at treating autoimmune disorders, with a focus on type 1 diabetes and inflammatory bowel disease. Enthera's pipeline targets key pathways involved in cell apoptosis in the gut, pancreas, and other organs to combat these intractable conditions effectively.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative implantable medical devices aimed at restoring vision for individuals blinded by the degeneration of photoreceptor cells in the retina. The company’s flagship product, the PRIMA System, is a bionic vision system designed to improve visual acuity and enhance the independence of patients. Pixium Vision also works on the Intelligent Retinal Implantable System (IRIS1), which is currently undergoing clinical trials, and is developing two subsequent generations, IRIS2 and IRIS3, each designed to provide improved visual capabilities through advanced technologies. Founded in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with prestigious institutions such as Stanford University and Moorfields Eye Hospital to further its research and development efforts in retinal implant systems.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

PinCell is a biotechnology company dedicated to developing innovative treatments for dermatological diseases, particularly those that are orphan conditions. The company focuses its research on identifying novel therapeutic molecules that target specific pathways involved in the pathomechanisms of inflammatory and neoplastic skin diseases. By addressing unmet medical needs in this area, PinCell aims to provide effective therapies for patients suffering from various skin disorders. Through its commitment to research and development, the company seeks to advance the understanding and treatment of these challenging conditions.

Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.

Epsilen Bio Srl is a biotechnology company based in Milan, Italy, specializing in the development of transformative therapies for patients with underserved medical conditions. Founded in December 2019, the company focuses on genomic epigenetic silencing, a technique aimed at stably silencing genes that contribute to various pathological processes. By leveraging this innovative approach, Epsilen Bio aims to provide new therapeutic options that address significant gaps in current medical treatments, ultimately enhancing patient care and outcomes.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Redx Pharma is a UK-based biotechnology company established in 2010, specializing in drug discovery and development. It focuses on improving existing drug classes to create best-in-class new drugs for cancer, fibrosis, and related diseases. The company's portfolio includes RXC004 (porcupine inhibitor) in Phase I clinical trials for various cancers, ROCK inhibitors for inflammatory disease-related fibrosis, and Pan-RAF inhibitor for colorectal cancer. Redx Pharma has collaborations with global pharmaceutical companies and the NHS.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Comet Therapeutics, established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing novel small-molecule treatments for various diseases, with a focus on orphan neurological disorders. The company's core technology is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism, thereby addressing significant unmet medical needs in these areas.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

InCarda Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. Founded in 2009 and based in Newark, California, the company specializes in a novel inhaled treatment approach to manage acute cardiovascular conditions. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic drug designed to treat paroxysmal atrial fibrillation quickly, allowing patients to administer the therapy in various settings, such as at home or work. By delivering medication directly to cardiac tissue, InCarda's therapy aims to provide effective treatment for atrial arrhythmias with a simplified approach. The company has completed Phase 1 clinical trials and is currently advancing its lead product through Phase 2 trials.

Enthera is an Italian biotechnology startup established in October 2016 by BiovelocITA, Professor Paolo Fiorina, and Dr. Francesca D'Addio. The company specializes in developing biotherapeutics aimed at treating autoimmune disorders, with a focus on type 1 diabetes and inflammatory bowel disease. Enthera's pipeline targets key pathways involved in cell apoptosis in the gut, pancreas, and other organs to combat these intractable conditions effectively.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

SafeHeal is a medical device company specializing in digestive surgery. It develops and manufactures a vacuum-based, flexible bypass sheath designed to protect a gastrointestinal anastomosis after colorectal cancer surgery, remaining in place during healing to reduce ostomy needs and support postoperative recovery. The company originated as the first venture created and incubated by MD Start, a medtech accelerator, with backing from MD Start and Sofinnova Partners.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Breath Therapeutics GmbH, based in Munich, Germany, with an additional office in Menlo Park, California, specializes in developing innovative drug-aerosol therapeutics aimed at treating bronchiolitis obliterans syndrome and other severe respiratory diseases. Founded in 2016 and operating as a subsidiary of Zambon S.p.A., the company focuses on creating novel formulations of existing drugs combined with advanced inhalation technologies. Their drug-device combinations are designed to deliver high concentrations of therapeutics directly to the lungs, enhancing efficacy while minimizing systemic exposure. This approach targets rare respiratory diseases with significant unmet medical needs, positioning Breath Therapeutics at the forefront of inhalation therapy advancements.

myTomorrows is an independent organization based in the Netherlands that focuses on improving access to treatments currently in development for patients with unmet medical needs. The company provides both patients and their doctors with comprehensive information about available treatment options worldwide, ensuring they are informed and can navigate administrative hurdles. By collaborating with medicine manufacturers, myTomorrows facilitates early access to innovative therapies for those who have exhausted viable treatment options. The organization has developed a Knowledge Base that integrates extensive medical and clinical data, offering an actionable overview of the full clinical development pipeline. This platform aims to enhance understanding and accessibility, ultimately supporting patients in finding the care they need.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating first-in-class cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. Utilizing a proprietary siRNA-based screening technology, iOmx systematically analyzes human tumor cells to identify innovative therapeutic targets and understand their mechanisms of action. The company's approach is rooted in the principles of cancer immune-checkpoint therapy, which aims to overcome tumors' inherent resistance to immune attacks. This resistance is often mediated by cell surface molecules that inhibit T cell activation. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

Delinia, Inc. is a biotechnology company based in San Francisco, California, founded to develop innovative therapeutics targeting autoimmune and inflammatory diseases. The company's primary focus is on a molecule designed to selectively potentiate and expand regulatory T cells (Tregs), which play a vital role in maintaining immune system homeostasis and self-tolerance. Delinia's lead program aims to enhance the function of these powerful immune cells, providing potential new treatment avenues for patients suffering from autoimmune conditions. Since its incorporation in 2014, Delinia has been guided by a team of scientific founders and experienced executives dedicated to advancing its therapeutic programs into clinical development.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

ENYO Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, with additional operations in Melbourne, Australia. Founded in 2014, it focuses on discovering and developing antiviral therapies by studying virus-host interactions within the human protein interaction network and leveraging its drug discovery platform to identify intracellular targets and molecules. The company's pipeline includes EYP001, a lead compound that modulates FXR, aiming to reduce the hepatitis B virus cccDNA reservoir and suppress viral transcription, and EYP002 for preclinical development. It also conducts toxicology testing for antiviral candidates against multiple viruses, including influenza, and pursues additional programs aimed at chronic hepatitis B and other infectious diseases. ENYO collaborates with researchers and institutions in Lyon, including Inserm and related biopole ecosystems, to advance its programs through early-stage clinical development and preclinical studies. The company aims to translate virus-host interaction biology into therapeutics for infectious diseases and related liver and metabolic conditions.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

ReCor Medical is a medical device company focused on treating resistant hypertension with a non-focused therapeutic ultrasound system for renal denervation. Its PARADISE technology comprises a six French catheter with a cylindrical transducer that delivers circumferential ultrasound energy to the renal nerves, while water-based cooling protects the renal artery and enables efficient nerve ablation. The system aims to reduce sympathetic nerve activity to lower blood pressure. The company designs, develops and manufactures this ultrasound ablation system and markets it through distributors in Northern Europe, Scandinavia, and Italy. ReCor Medical was founded in 2009 and is based in Palo Alto, California. In 2018, it became a subsidiary of Otsuka Holdings.

myTomorrows is an independent organization based in the Netherlands that focuses on improving access to treatments currently in development for patients with unmet medical needs. The company provides both patients and their doctors with comprehensive information about available treatment options worldwide, ensuring they are informed and can navigate administrative hurdles. By collaborating with medicine manufacturers, myTomorrows facilitates early access to innovative therapies for those who have exhausted viable treatment options. The organization has developed a Knowledge Base that integrates extensive medical and clinical data, offering an actionable overview of the full clinical development pipeline. This platform aims to enhance understanding and accessibility, ultimately supporting patients in finding the care they need.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.